Expanded collaborative research initiatives reinforce the Company's long-term DNase development stra

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targ

New preclinical and translational findings position DNase I as a potentially transformative adjunct

Advancements across investigator-initiated studies, translational research and manufacturing activit

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xeneti

Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - Get Fr

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in d

Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Ainos (NASDAQ: AIMD - Get Free Report) are

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a large growth in sh

Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO -

Crinetics Pharmaceuticals (NASDAQ: CRNX - Get Free Report) and Xenetic Biosciences (NASDAQ: XBIO - G

Xenetic Biosciences, Inc. (NASDAQ: XBIO - Get Free Report) was the recipient of a significant declin

Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In F

FRAMINGHAM, MA / ACCESS Newswire / November 19, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xen

Continued execution on collaborations and exploratory investigator-initiated studies with institutio

FRAMINGHAM, MA / ACCESS Newswire / October 10, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xene

Healthcare and biotech stocks have lagged broader markets this year, but a growing number of names h

Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studi

Xenetic Biosciences (XBIO) came out with a quarterly loss of $0.45 per share versus the Zacks Consen

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv S

Research and development collaboration program to include additional models of lymphoma and leukemia

  During Friday's trading, 293 companies set new 52-week lows.

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o

  During Friday, 125 stocks hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Tuesday morning saw 454 companies set new 52-week lows.

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 o

Gainers Zomedica Corp. (NYSE: ZOM) shares surged 92.2% to close at $0.93 on Monday after surging

Stocks That Hit 52-Week Lows On Thursday

Stocks That Hit 52-Week Lows On Wednesday

58 Biggest Movers From Yesterday

55 Biggest Movers From Yesterday

44 Stocks Moving In Monday's Mid-Day Session